ApoB Goal Cost-Effective in Primary Prevention

• by Kathryn Wighton

• April 15, 2026

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

• by Kathryn Wighton

• August 28, 2026

• 4 min

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.

• by mdspire news news staff

• July 10, 2026

• 7 min

Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis

• by Tate M. Johnson, Halie Frideres, Punyasha Roul, Joshua F. Baker, Brian C. Sauer, Grant W. Cannon, Isaac D. Smith, Gary A. Kunkel, Beth I. Wallace, Thomas R. Porter, Kaveh R. Bookani, Amarnath R. Annapureddy, Ted R. Mikuls, Bryant R. England

• July 1, 2026